Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Acute Neurological Inflammatory Diseases in Colombia: A Multi-center Observational Study from Zika outbreak to SARS-CoV-2 pandemic
Autoimmune Neurology
S3 - Autoimmune Neurology 1: Mechanisms of Disease, Clinical Practice (1:12 PM-1:24 PM)
002
The outbreak of Zika virus infection in Colombia in 2015-2016, produced an increased incidence of Guillain-Barré Syndrome (GBS) and other ANID cases. The Neuroviruses Emerging in the Americas Study (NEAS) network was established in 2016 as a multicenter-based observatory of ANIDs to investigate the role of emerging pathogens in neuroinflammatory diseases.
To evaluate clinical, laboratory, and epidemiological features of acute neuroinflammatory disorders (ANIDs) that followed the 2016 Zika epidemic in Colombia.
NEAS serves as a multi-center study based on 13 hospitals in 7 cities in Colombia which study all newly diagnosed patients who fulfill established criteria for GBS, encephalitis, myelitis, meningoencephalitis, or cranial nerve disorders as part of an observational cohort. We analyzed the clinical and epidemiological features of all cases evaluated between January 2016 and September 2021.
An observational cohort of 825 patients with ANIDs were recruited during the study period. 58.8% of cases were male with a median age of 43 (IQR 25-58) years. The most frequent ANIDs were GBS (46.1%) and facial nerve palsy (28.7%). The diagnosis of encephalitis (9.5%), myelitis (6.5%), and optic neuritis (5.9%) were less frequent. Patients with GBS were predominantly male (70.6%) and had a median age of 49 (IQR 32-60) years. Interestingly, there was an increase incidence of GBS in 2019.
The outbreak of Zika in Colombia produced a marked increase in the incidence of GBS in 2016. Although cases of GBS and other ANIDs continued to emerge after the incidence of Zika infection decreased in July 2016, the recent SARS-CoV-2 pandemic has not produced any significant increase in the incidence of GBS in Colombia.
Authors/Disclosures
Susana Dominguez Penuela (Johns Hopkins University School of Medicine)
PRESENTER
Dr. Dominguez Penuela has nothing to disclose.
No disclosure on file
Jose Enrique Vargas Manotas (Private Office) Dr. Vargas Manotas has nothing to disclose.
No disclosure on file
No disclosure on file
Jairo Francisco Lizarazo Nino (Tecnofarma) No disclosure on file
Jorge Angarita Dr. Angarita has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
David Acero-Garces (Johns Hopkins University) The institution of Dr. Acero-Garces has received research support from Ministry of Science, Technology and Innovation of Colombia.
Maria Garcia-Dominguez (UMass Memorial Medical Center) Dr. Garcia-Dominguez has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Gustavo Ramos (Universidad Libre De Cali, Universidad Del Valle, Clinica Dime) Dr. Ramos has nothing to disclose.
No disclosure on file
No disclosure on file
Angela Catalina Vallejo Cajigas (angela catalina vallejo cajigas) Dr. Vallejo Cajigas has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Carlos Pardo-Villamizar (Johns Hopkins U, Med Dept of Neurology) The institution of Dr. Pardo-Villamizar has received research support from National Institutes of Health. The institution of Dr. Pardo-Villamizar has received research support from Bart McLean Fund for Neuroimmunology Research .